{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:24:47Z","timestamp":1787318687501,"version":"build-2736575974"},"reference-count":21,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Fabry disease (FD) is an X-linked lysosomal disorder caused by mutations in GLA gene resulting in lack of or faulty \u03b1-galactosidase A (\u03b1-GalA) enzyme. Enzyme replacement therapy (ERT) with recombinant human \u03b1-GalA enzyme (agalsidase) is the standard treatment option for FD. Infusion-related reactions (IRRs), with symptoms ranging from rigors, to fever, pain, vomiting, angioedema and diarrhea, are often seen due to immune response against the exogenous enzyme. To elucidate the mechanisms causing the IRRs in FD, eight patients who developed IRRs were investigated. All, except one, tested negative for agalsidase-specific IgE and had normal tryptase levels. Circulating dendritic cells were drastically reduced during IRRs, suggesting possible sequestration to the sites of inflammation. An increase in NK cells and a decrease in T cells were also observed. Cytokines IL-4, IL-8 and TNF-\u03b1 showed a significant increase, indicating nonspecific degranulation of mast cells. All IRRs were managed successfully using a combination of standard premedications and mast cell stabilizers without any interruption of therapy. Taken together, the results indicate crosstalk between immune cells resulting in IgE-independent mast-cell-specific allergic inflammation. Mast cell stabilizers could be used to control IRRs and for safe reintroduction of agalsidase in patients previously treated with ERT.<\/jats:p>","DOI":"10.3390\/ijms21197213","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T20:56:22Z","timestamp":1601412982000},"page":"7213","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Interaction of Innate and Adaptive Immunity and Stabilization of Mast Cell Activation in Management of Infusion Related Reactions in Patients with Fabry Disease"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6957-6284","authenticated-orcid":false,"given":"Renuka P.","family":"Limgala","sequence":"first","affiliation":[{"name":"Translational Research Unit, Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA 22030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaqueline","family":"Fikry","sequence":"additional","affiliation":[{"name":"Translational Research Unit, Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA 22030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasudha","family":"Veligatla","sequence":"additional","affiliation":[{"name":"Translational Research Unit, Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA 22030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4758-6793","authenticated-orcid":false,"given":"Ozlem","family":"Goker-Alpan","sequence":"additional","affiliation":[{"name":"Translational Research Unit, Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA 22030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: Management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Turkmen, K., and Baloglu, I. (2020). Fabry disease: Where are we now?. Int. Urol. Nephrol.","DOI":"10.1007\/s11255-020-02546-3"},{"key":"ref_4","first-page":"30","article-title":"Enzyme replacement therapy in patients with Fabry disease: State of the art and review of the literature","volume":"30","author":"Riccio","year":"2013","journal-title":"G. Ital. Nefrol. Organo Uff. Della Soc. Ital. Nefrol."},{"key":"ref_5","first-page":"100454","article-title":"The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts","volume":"19","author":"Germain","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_7","first-page":"Cd006663","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","volume":"7","author":"Gomaa","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_8","unstructured":"Genzyme Corporation (2003). Fabrazyme (Agalsidase Beta), Genzyme Corporation."},{"key":"ref_9","unstructured":"Shire Human Genetic (2001). Replagal (Agalsidae Alfa), Therapies Inc."},{"key":"ref_10","unstructured":"Mehta, A., Beck, M., and Sunder-Plassmann, G. (2006). Safety of enzyme replacement therapy. Fabry Disease: Perspectives from 5 Years of FOS, Oxford PharmaGenesis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","article-title":"Fabry disease, enzyme replacement therapy and the significance of antibody responses","volume":"35","author":"Deegan","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2011.09.007","article-title":"The role of mast cells in allergic inflammation","volume":"106","author":"Amin","year":"2012","journal-title":"Respir. Med."},{"key":"ref_13","first-page":"1683","article-title":"Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta","volume":"11","author":"Limgala","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1111\/j.1398-9995.2010.02459.x","article-title":"Natural killer-dendritic cell interaction in lymphocyte responses in hypersensitivity reactions to betalactams","volume":"65","author":"Chaves","year":"2010","journal-title":"Allergy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2007.09.047","article-title":"Perturbations of natural killer cell regulatory functions in respiratory allergic diseases","volume":"121","author":"Scordamaglia","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.coi.2005.03.004","article-title":"The dialogue between human natural killer cells and dendritic cells","volume":"17","author":"Moretta","year":"2005","journal-title":"Curr. Opin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/ACI.0b013e3283489bab","article-title":"Role of dendritic cells in drug allergy","volume":"11","author":"Cuesta","year":"2011","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/00130832-200312000-00011","article-title":"Toll receptors modulate allergic responses: Interaction with dendritic cells, T cells and mast cells","volume":"3","author":"Bellou","year":"2003","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_19","first-page":"620","article-title":"Mast Cell: A Multi-Functional Master Cell","volume":"6","author":"Dileepan","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/dmrr.1272","article-title":"Mast cell stabilization: Novel medication for obesity and diabetes","volume":"27","author":"Wang","year":"2011","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Limgala, R.P., Ioanou, C., Plassmeyer, M., Ryherd, M., Kozhaya, L., Austin, L., Abidoglu, C., Unutmaz, D., Alpan, O., and Goker-Alpan, O. (2016). Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0168135"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/19\/7213\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:15:00Z","timestamp":1760177700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/19\/7213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":21,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["ijms21197213"],"URL":"https:\/\/doi.org\/10.3390\/ijms21197213","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]}}}